Bayer Guns For Top-Three Pharmaceutical Seat In China
This article was originally published in PharmAsia News
Greater China has been the fastest-growing region for Bayer HealthCare; its pharmaceutical business there increased 30 percent to achieve revenue of €1.8 billion in 2007 ($2.8 billion). The company attributes the success to its focus on OTC business. Generics, especially OTC drugs, will form the core of Bayer's growth in China after 2008 and it aims to be among the top three health care MNCs. However, some gaps need plugging: the firm has yet to launch in the country its top three blockbuster drugs, namely, Betaferon (interferon beta-1b), Yasmin (drospirenone/ethinyl estradiol) and Kogenate (recombinant clotting factor VIII). Bayer Schering Pharma plans to launch all its global heavyweights in China within three years and introduce over 20 new products within five years. (Click here for more - Chinese Language)
You may also be interested in...
BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound
Pfizer and Moderna’s ‘endemic’ COVID vaccine market scenarios anticipate much higher booster rates than have been achieved so far, but performance for 2023 may be aided by the Biden Administration campaign to increase shots this winter.
Regeneron President George Yancopoulos got in a screaming match at Milken conference, arguing paying for cures is a secondary problem that should be tackled once such products are developed. He also talked about how he believes tech companies are helping to create some of America’s health crises.